Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

BUSM & BMC win GCE grant to develop next-generation condom using nanotechnology

BUSM & BMC win GCE grant to develop next-generation condom using nanotechnology

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Domino transplant saves patient suffering from liver cancer

Domino transplant saves patient suffering from liver cancer

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

BMC, BUSM and JIPMER to jointly research on tuberculosis

BMC, BUSM and JIPMER to jointly research on tuberculosis

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

PET with 11C-PIB can positively visualize amyloid deposits in the heart

PET with 11C-PIB can positively visualize amyloid deposits in the heart

Amyloid clue to Parkinson’s dementia

Amyloid clue to Parkinson’s dementia

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam advances Tuschl II patent estate through the USPTO

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Gene silencing technology used to fight RSV and influenza

Gene silencing technology used to fight RSV and influenza

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million